Lidocaine Powder Local Anesthetics CAS:137-58-6
Lidocaine, a cornerstone of modern local anesthesia, exists in various forms, with its powdered version being the pure, unadulterated base for pharmaceutical formulations. Discovered in 1943 by Swedish chemist Nils Löfgren, lidocaine revolutionized pain management by offering a safer, more effective alternative to procaine.
Introduction to Lidocaine Powder
Lidocaine, a cornerstone of modern local anesthesia, exists in various forms, with its powdered version being the pure, unadulterated base for pharmaceutical formulations. Discovered in 1943 by Swedish chemist Nils Löfgren, lidocaine revolutionized pain management by offering a safer, more effective alternative to procaine. The powder form, a white crystalline substance (chemical formula: C₁₄H₂₂N₂O), serves as the foundational ingredient in injectables, topical creams, and transdermal patches. Unlike commercial preparations, lidocaine powder allows customizable compounding, catering to specific clinical needs.
Chemical and Physical Features
Lidocaine's molecular structure includes an aromatic benzene ring linked to an amide group, classifying it as an aminoamide anesthetic. Key features:
●Solubility: Highly soluble in water and alcohol, facilitating diverse formulations.
●Stability: Degrades under prolonged exposure to light or high pH, necessitating storage in amber vials at controlled temperatures (15–30°C).
●Polymorphism: Exhibits multiple crystalline forms, impacting dissolution rates and bioavailability. Form I (monoclinic) is most stable, preferred for pharmaceutical use.
●pKa: 7.9, enabling effective tissue penetration at physiological pH.
Mechanism of Action
Lidocaine blocks voltage-gated sodium channels in neuronal membranes, inhibiting depolarization and impulse propagation. Recent studies highlight its interaction with specific channel subtypes (Nav1.7–Nav1.9), crucial in pain signaling. Unlike ester anesthetics, lidocaine's amide bond resists hydrolysis by plasma esterases, prolonging its effect and reducing allergic potential.
Applications in Medicine
●Surgical Anesthesia: Widely used in dental, dermatological, and minor surgical procedures.
●Topical Analgesia: Incorporated in creams (5–10%) for burns, shingles, or mucosal surfaces.
●Regional Blocks: Epidural or nerve block injections for orthopedic surgeries.
●Cardiac Use: Intravenous administration treats ventricular arrhythmias (off-label).
●Veterinary Medicine: Safe for cats and dogs in dental extractions or wound suturing.
●Neuropathic Pain: Emerging role in managing diabetic neuropathy via sustained-release formulations.
Benefits Over Other Anesthetics
●Rapid Onset: Achieves numbness within 2–5 minutes.
●Duration: Lasts 1–2 hours, extendable with vasoconstrictors like epinephrine.
●Lower Allergenicity: Rare hypersensitivity compared to ester-types (e.g., benzocaine).
●Cost-Effectiveness: Synthesized from xylidine, an inexpensive precursor.
●Versatility: Compatible with adjuvants (bicarbonate, opioids) to enhance efficacy.
Dosage Guidelines
Dosage varies by application:
●Infiltration Anesthesia: 4.5 mg/kg (max 300 mg without epinephrine).
●Topical: 3–5% cream applied sparingly to intact skin.
●Intravenous (Arrhythmias): 1–1.5 mg/kg bolus, followed by 1–4 mg/min infusion.
●Epidural: 200–300 mg with epinephrine (1:200,000) for labor analgesia.
Note: Exceeding 7 mg/kg risks systemic toxicity.
Pharmacokinetics
●Absorption: Rapid from mucous membranes; slower through intact skin.
●Distribution: 70% protein-bound, with high affinity for adipose tissue.
●Metabolism: Hepatic CYP1A2 and CYP3A4 convert it to active metabolites (e.g., monoethylglycinexylidide).
●Excretion: Renal (90%); dose adjustment needed in hepatic impairment.
Half-Life and Influencing Factors
●Half-Life: 1.5–2 hours in healthy adults. Prolonged in:
○Liver Dysfunction: Reduced clearance.
○Elderly: Decreased hepatic blood flow.
○Drug Interactions: CYP inhibitors (e.g., fluvoxamine) increase toxicity risk.
Safety, Toxicity, and PTC Considerations
●Toxicity Threshold: Plasma levels >5 μg/mL cause CNS effects (tinnitus, seizures); >10 μg/mL risks cardiac arrest.
●Management: Lipid emulsion therapy (Intralipid®) binds lidocaine, reversing toxicity.
●PTC Interpretation: If referencing "Plasma Therapeutic Concentration," target 1.5–5 μg/mL. For "Pediatric Toxicity Concerns," doses are weight-adjusted (max 3 mg/kg).
Special Considerations
●Pregnancy: Category B; safe for epidural use but avoid high doses.
●Interactions: Beta-blockers reduce hepatic metabolism; succinylcholine may potentiate neuromuscular blockade.
●Methemoglobinemia: Rare risk with excessive topical use; treat with methylene blue.
Regulatory and Handling Guidelines
●Storage: Airtight containers, protected from humidity.
●Compounding: USP <795> standards mandate sterile techniques for injectables.
●Disposal: Incinerate to prevent environmental contamination.
Recent Advances and Research
●Nanoparticle Delivery: Enhances transdermal penetration for chronic pain.
●Gene Therapy: Studies explore lidocaine's role in silencing pain-associated genes.
●Eco-Friendly Synthesis: Green chemistry approaches reduce xylidine waste.
Clinical Data
|
Trade Names |
Lidocaine,Xylocaine, Ztlido,Lignocaine |
|
CAS |
137-58-6 |
|
Molar mass |
234.343 |
|
Formula |
C14H22N2O |
|
Purity |
Above 98% |
|
Apprarance |
White Crystalline Powder |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885
Conclusion
Lidocaine powder remains indispensable in anesthesia due to its adaptability, efficacy, and safety. Ongoing innovations promise expanded applications, from targeted drug delivery to genetic pain modulation, ensuring its relevance in future medical practice.
Hot Tags: lidocaine powder local anesthetics cas:137-58-6, China lidocaine powder local anesthetics cas:137-58-6 manufacturers, suppliers, factory, Anabolic Esters Boldenone Cypionate, Anabolic Sterol Esters Clostebol Acetate, Clomid Treatment of female anovulatory infertility, Testosterone Acetate, Trenbolone Acetate, Turinabol
